G

ood morning, everyone, and how are you today? We are just fine, thank you, since a shiny sun and delicious breeze are enveloping the Pharmalot campus. We hope things are just as delightful wherever you may be. Now, though, the time has come to get cracking. Before we continue, however, we would like to note that we will break for a couple of days in observance of ancient traditions. But we will be back before you can say Jack Robinson, or Donald Trump, or how about Bernie Sanders? Well, whatever. Best of luck during the rest of the week and see you soon …

The U.K.’s National Institute for Health and Care Excellence recommended the Opdivo immunotherapy as a second-line treatment for some forms of lung cancer after Bristol-Myers Squibb (BMY) agreed to discount the price, Pharmaphorum explains. The arrangement comes a year after the cost-effectiveness watchdog initially offered to recommend coverage only for about one-third of the 1,300 eligible patients.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.